Biotech RadarJobs updated

COMPANY

Assembly Biosciences

HQ: South San Francisco, CA source · assemblybio.com ↗ · West Coast

Clinical Phase 2

4 open jobs · last seen Oct 23, 2026 · 24 sources

Assembly Biosciences is listed on ClinicalTrials.gov as the lead sponsor of 23 studies; the most recently updated is “A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function” (Phase 1, not yet recruiting), in Mild Hepatic Imparement. From public records Source · Oct 12, 2026

Keywords: Chronic Hepatitis B Recurrent Genital Herpes Simplex Type 2 Mild Hepatic Imparement Chronic Hepatitis D Infection Hepatitis Delta Virus Hepatitis D Ulcerative Colitis Chronic Mild Ulcerative Colitis Chronic Moderate ABI-H0731 ABI-H2158 ABI-5366 ABI-1179 ABI-4334 AB-729 ABI-H3733 ABI-M201 Vebicorvir

Profile checked Oct 10, 2026

4Open jobs$115.0MRaised (2 yrs)23Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Research Associate, Clinical VirologySouth San Francisco, CaliforniaNot statedOct 11, 2026
Research Associate, Discovery BiologySouth San Francisco, CaliforniaNot statedOct 11, 2026
Director, Medicinal ChemistrySouth San Francisco, CaliforniaNot statedOct 11, 2026
Senior Manager, Process Development and ManufacturingSouth San Francisco, CaliforniaNot statedOct 11, 2026

See all 4 jobs

Timeline

  1. Trial start Phase 1: A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function source ↗
  2. Trial start Phase 2: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection source ↗
  3. Raise Follow-on offering: $115M (total, as published), announced May 26, 2026. Source: SEC filing. source ↗
  4. Trial start Phase 1: A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants source ↗
  5. Trial start Phase 1: A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes source ↗
  6. Trial start Phase 1: A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection source ↗
  7. Trial start Phase 1: A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes source ↗
  8. Trial start Phase 1: A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects source ↗
  9. Trial start Phase 1: A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection source ↗
  10. Trial start Phase 2: A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection source ↗
  11. Trial start Phase 2: A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection source ↗
  12. Trial start Phase 1: A Study to Evaluate the Mass Balance Absorption and AME of VBR source ↗
  13. Trial start Phase 2: A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors source ↗
  14. Trial start Phase 2: A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection source ↗
  15. Trial start Phase 1: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults source ↗
  16. Trial start Phase 1: A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults source ↗
  17. Trial start Phase 1: A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults source ↗
  18. Trial start Phase 1: ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis source ↗
  19. Trial start Phase 2: A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients source ↗
  20. Trial start Phase 1: A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B source ↗
  21. Trial start Phase 2: A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) source ↗
  22. Trial start Phase 2: A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection source ↗
  23. Trial start 1: Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B source ↗
  24. Trial start Phase 1: A Study in Healthy Volunteers and Patients With Chronic Hepatitis B source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $115.0M. Last 2 years.

Clinical trials (lead sponsor) 23

RecordTitlePhaseStatusStartPrimary completion
NCT07850999A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic FunctionPhase 1Not yet recruiting2026-102027-04 (estimated)
NCT07762027A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus InfectionPhase 2Not yet recruiting2026-102027-06 (estimated)
NCT06385327A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital HerpesPhase 1CompletedMay 30, 2024Feb 3, 2026 (actual)
NCT06698575A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital HerpesPhase 1CompletedDec 8, 2024Jan 19, 2026 (actual)
NCT06740474A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy ParticipantsPhase 1CompletedJan 31, 2025Jul 8, 2025 (actual)
NCT06384131A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus InfectionPhase 1CompletedJun 4, 2024Apr 15, 2025 (actual)
NCT04820686A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B InfectionPhase 2TerminatedMay 7, 2021Mar 30, 2023 (actual)
NCT04781647A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus InfectionPhase 2TerminatedFeb 18, 2021Dec 2, 2022 (actual)
NCT05569941A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy SubjectsPhase 1CompletedNov 11, 2022Apr 12, 2023 (actual)
NCT05414981A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus InfectionPhase 1CompletedAug 7, 2022Apr 24, 2023 (actual)
NCT03780543A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B PatientsPhase 2TerminatedDec 20, 2018Apr 26, 2021 (actual)
NCT04454567A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase InhibitorsPhase 2TerminatedNov 11, 2020Apr 8, 2021 (actual)
NCT04398134A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus InfectionPhase 2TerminatedAug 28, 2020Oct 14, 2021 (actual)
NCT03923478ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative ColitisPhase 1TerminatedJun 24, 2019Jan 20, 2021 (actual)
NCT03576066A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B InfectionPhase 2CompletedJun 11, 2018Jul 5, 2019 (actual)
NCT03577171A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)Phase 2CompletedJun 19, 2018Jun 21, 2019 (actual)
NCT03714152A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis BPhase 1CompletedNov 13, 2018Nov 23, 2020 (actual)
NCT04271592A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy AdultsPhase 1CompletedMay 17, 2020Nov 3, 2020 (actual)
NCT04637139A Study to Evaluate the Mass Balance Absorption and AME of VBRPhase 1CompletedDec 1, 2020Dec 22, 2020 (actual)
NCT04142762A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy AdultsPhase 1CompletedOct 18, 2019Jan 12, 2020 (actual)
NCT04083716A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy AdultsPhase 1CompletedSep 6, 2019Oct 5, 2019 (actual)
NCT02908191A Study in Healthy Volunteers and Patients With Chronic Hepatitis BPhase 1Completed2016-11Mar 31, 2018 (actual)
NCT03109730Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B1CompletedJun 15, 2017Mar 31, 2018 (actual)

Open jobs 4

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Research Associate, Clinical VirologySouth San Francisco, CaliforniaNot statedOct 11, 2026Mid
Research Associate, Discovery BiologySouth San Francisco, CaliforniaNot statedOct 11, 2026Entry
Director, Medicinal ChemistrySouth San Francisco, CaliforniaNot statedOct 11, 2026Senior
Senior Manager, Process Development and ManufacturingSouth San Francisco, CaliforniaNot statedOct 11, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Assembly Biosciences on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback